Cornell researchers have identified a key protein mechanism that helps bacteria expel antibiotics, making them more resistant ...
Research into developing new antimicrobial resistance treatment in Nigeria and other low/middle-income countries has fuelled ...
A Cornell University-led collaboration has uncovered the equipment that enables bacteria to survive exposure to antibiotics: ...
AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...
AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...
Research into developing new antimicrobial resistance treatments in Nigeria and other low/middle-income countries has secured ...
It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...
AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
CAMBRIDGE, MA AND PITTSBURGH, PA / ACCESSWIRE / 10, 2025 / Next Gen Diagnostics (NGD), a pioneer in the development of machine learning models for whol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback